Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
City of Hope Medical Center
BeOne Medicines
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
City of Hope Medical Center
National Cancer Institute (NCI)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
MitoImmune Therapeutics
Tampere University Hospital
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals